NASDAQ:ASND

Ascendis Pharma A/s Stock News

etoro logo Buy ASND
*Your capital is at risk
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “buy” rating reaffirmed by stock analysts at Bank of America in a report issued on Friday, AnalystRatings.com reports. They currently have a $14
Merrill Lynch analyst Tazeen Ahmad maintained a Buy rating on Ascendis Pharma ( ASND – Research Report ) on March 23 and set a price target of $145.00 . The company’s shares closed last Monday at
Zacks Investment Research upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a research note released on Tuesday morning, Zacks.com reports. Zacks Investment Re
BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.
BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.
COPENHAGEN, Denmark, March 25, 2020 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet.
Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.
Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday, BidAskClub reports. ASND has been the subject of a number o
Barclays PLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 95.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 378 share
Analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings per share (EPS) of ($1.29) for the current quarter, according to Zacks. Three analysts have issued estimates for Ascendi
Oppenheimer initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report released on Thursday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $199.00
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE